AN2 Therapeutics, Inc.
NASDAQ: ANTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric E. Easom
- Employees
- 22
- Headquarters
- Menlo Park, United States
- IPO year
- 2022
- Market cap
- $142.5M
- Website
- https://www.an2therapeutics.com
Loading ANTX…
Loading profile data…Frequently asked questions about ANTX
What does AN2 Therapeutics, Inc. (ANTX) do?
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling c...
Where does ANTX trade?
AN2 Therapeutics, Inc. (ANTX) trades on the NASDAQ Global Select.
What sector is ANTX in?
AN2 Therapeutics, Inc. (ANTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AN2 Therapeutics, Inc.?
Eric E. Easom is the chief executive officer of AN2 Therapeutics, Inc. (ANTX).
Where is AN2 Therapeutics, Inc. headquartered?
AN2 Therapeutics, Inc. is headquartered in United States.
Does ANTX pay a dividend?
AN2 Therapeutics, Inc. (ANTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANTX go public?
AN2 Therapeutics, Inc. (ANTX) completed its initial public offering in 2022.